Successful treatment of feline hyperadrenocorticism with pituitary macroadenoma using radiation therapy: a case study

J Vet Med Sci. 2022 Jul 1;84(7):898-904. doi: 10.1292/jvms.22-0021. Epub 2022 May 5.

Abstract

A 10-year-old castrated male cat showing behavioral (irritation, prowling, and tumbling) and cutaneous abnormalities such as dermal fragility was diagnosed as hyperadrenocorticism with pituitary macroadenoma, concurrent with insulin dependent diabetes mellitus. Pituitary enlargement (18.0 mm) was observed during magnetic resonance imaging. High endogenous adrenocorticotropic hormone levels (>2,500 pg/ml) were also observed. Although trilostane treatment (5-10 mg/head, daily) was commenced, the clinical signs did not disappear. Insulin and trilostane treatment were discontinued on day 86 after first day of radiation therapy (4 Gy/12 fractions). After radiation therapy, a decreased pituitary tumor size (10.7 mm) was observed on day 301; neurological and dermatological signs exhibited remission. Radiation therapy is the treatment of choice for feline hyperadrenocorticism with pituitary macroadenoma with neurological signs.

Keywords: adrenocorticotropic hormone; cortisol; dermatological sign; neurological sign; trilostane.

MeSH terms

  • Adrenocortical Hyperfunction* / radiotherapy
  • Adrenocortical Hyperfunction* / veterinary
  • Animals
  • Cat Diseases* / drug therapy
  • Cats
  • Dihydrotestosterone / therapeutic use
  • Dog Diseases* / pathology
  • Dogs
  • Hydrocortisone
  • Magnetic Resonance Imaging / veterinary
  • Male
  • Pituitary Gland
  • Pituitary Neoplasms* / diagnosis
  • Pituitary Neoplasms* / radiotherapy
  • Pituitary Neoplasms* / veterinary

Substances

  • Dihydrotestosterone
  • Hydrocortisone